STAT6 and COVID-19: In individuals with type-2 inflammation, such as asthma, O-GlcNAc activation of STAT6 might also compromise frontline antiviral defenses, as STAT6 induces IL-25 that suppresses the production of type I and III interferons, as shown in rhinovirus infection [64], and through IL-33, can drive a “type-2 cytokine storm”, as observed in COVID-19 and influenza infections [65].